ES2318276T3 - Uso de los derivados de la isoquinolina para tratar el cancer y las enfermedades relacionadas con la quinasa map. - Google Patents

Uso de los derivados de la isoquinolina para tratar el cancer y las enfermedades relacionadas con la quinasa map. Download PDF

Info

Publication number
ES2318276T3
ES2318276T3 ES04718960T ES04718960T ES2318276T3 ES 2318276 T3 ES2318276 T3 ES 2318276T3 ES 04718960 T ES04718960 T ES 04718960T ES 04718960 T ES04718960 T ES 04718960T ES 2318276 T3 ES2318276 T3 ES 2318276T3
Authority
ES
Spain
Prior art keywords
baselineskip
phenyl
substituted
alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04718960T
Other languages
English (en)
Spanish (es)
Inventor
David Bryant Batt
Guido Bold
Sunkyu Kim
Timothy Michael Ramsey
Michael Lloyd Sabio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2318276T3 publication Critical patent/ES2318276T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES04718960T 2003-03-11 2004-03-10 Uso de los derivados de la isoquinolina para tratar el cancer y las enfermedades relacionadas con la quinasa map. Expired - Lifetime ES2318276T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11
US453624P 2003-03-11

Publications (1)

Publication Number Publication Date
ES2318276T3 true ES2318276T3 (es) 2009-05-01

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04718960T Expired - Lifetime ES2318276T3 (es) 2003-03-11 2004-03-10 Uso de los derivados de la isoquinolina para tratar el cancer y las enfermedades relacionadas con la quinasa map.

Country Status (22)

Country Link
EP (1) EP1603566B1 (https=)
JP (1) JP2006519807A (https=)
KR (1) KR20050108383A (https=)
CN (1) CN1758910A (https=)
AT (1) ATE421324T1 (https=)
AU (1) AU2004218914A1 (https=)
BR (1) BRPI0408257A (https=)
CA (1) CA2518530A1 (https=)
DE (1) DE602004019193D1 (https=)
ES (1) ES2318276T3 (https=)
HR (1) HRP20050788A2 (https=)
IS (1) IS8064A (https=)
MA (1) MA27724A1 (https=)
MX (1) MXPA05009687A (https=)
NO (1) NO20054647L (https=)
PL (1) PL1603566T3 (https=)
PT (1) PT1603566E (https=)
RU (1) RU2325159C2 (https=)
TN (1) TNSN05223A1 (https=)
TW (1) TW200501955A (https=)
WO (1) WO2004080464A1 (https=)
ZA (1) ZA200506571B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
EP2258704A1 (en) 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
EP1863491A1 (en) * 2005-02-25 2007-12-12 Novartis AG Pharmaceutical combination of bcr-abl and raf inhibitors
RS52241B (sr) * 2005-07-26 2012-10-31 Sanofi Derivati cikloheksilamin izohinolona kao inhibitori rho-kinaze
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
JP2009077712A (ja) * 2007-09-11 2009-04-16 F Hoffmann La Roche Ag Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験
US8926561B2 (en) 2009-07-30 2015-01-06 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
BR112012022801B8 (pt) * 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
US9056855B2 (en) * 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
CA3104808A1 (en) * 2018-07-02 2020-01-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
PT1107964E (pt) * 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
DOP2000000070A (es) * 1999-09-28 2002-02-28 Bayer Healthcare Llc Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
ATE497603T1 (de) * 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
ATE421324T1 (de) 2009-02-15
RU2005131168A (ru) 2006-05-27
EP1603566B1 (en) 2009-01-21
TNSN05223A1 (en) 2007-06-11
BRPI0408257A (pt) 2006-03-07
TW200501955A (en) 2005-01-16
ZA200506571B (en) 2006-07-26
EP1603566A1 (en) 2005-12-14
JP2006519807A (ja) 2006-08-31
AU2004218914A1 (en) 2004-09-23
PT1603566E (pt) 2009-04-27
DE602004019193D1 (de) 2009-03-12
KR20050108383A (ko) 2005-11-16
IS8064A (is) 2005-10-10
NO20054647L (no) 2005-12-09
PL1603566T3 (pl) 2009-07-31
MXPA05009687A (es) 2005-10-20
NO20054647D0 (no) 2005-10-10
WO2004080464A1 (en) 2004-09-23
RU2325159C2 (ru) 2008-05-27
CA2518530A1 (en) 2004-09-23
CN1758910A (zh) 2006-04-12
HRP20050788A2 (en) 2006-12-31
MA27724A1 (fr) 2006-01-02

Similar Documents

Publication Publication Date Title
ES2342240T3 (es) Derivados de isoquinolina con actividad que inhibe la angiogenia.
ES2265929T3 (es) Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
ES2318276T3 (es) Uso de los derivados de la isoquinolina para tratar el cancer y las enfermedades relacionadas con la quinasa map.
ES2670550T3 (es) Derivados de quinolina selectivamente sustituidos
ES2234097T3 (es) Ftalazinas con actividad inhibidora de la angiogenesis.
ES2952281T3 (es) Compuestos deuterados para uso en el tratamiento del cáncer
KR102284031B1 (ko) Dna 알킬화제
JP6612892B2 (ja) 抗がん剤のニトロベンジル誘導体
ES2816060T3 (es) Aza-aril 1H-pirazol-1-il-bencenosulfonamidas como antagonistas de CCR(9)
ES2934432T3 (es) Compuestos de imidazopirazina, métodos de preparación y usos de los mismos
ES2244231T3 (es) Derivados de aminopirazol.
ES2266313T3 (es) Derivados de triazolodiamina sustituidos como inhibidores de la quinasa.
ES2898771T3 (es) Indazoles sustituidos útiles para el tratamiento y la prevención de enfermedades alérgicas y/o inflamatorias en animales
JP2007506696A (ja) 増殖性疾患の処置に有用なｒａｆ−キナーゼ阻害剤としての１，４−二置換イソキノリン誘導体
JP2019517564A (ja) シラノール系治療的ペイロード
KR20240024935A (ko) Pd-l1을 표적화하기 위한 방법 및 조성물
ES2967642T3 (es) Inhibidor de IRAK y método de preparación del mismo y uso del mismo
ES2648994T3 (es) Diazolamidas como antagonistas del receptor CCR1
ES2985738T3 (es) Compuestos de 2-oxindol
EA023642B1 (ru) Гетеробициклические производные в качестве ингибиторов hcv
ES2774501T3 (es) Etinos de amidoheteroaril aroil hidrazida novedosos
ES3051512T3 (en) Histone deacetylase inhibitors for immunomodulation in tumor microenvironment
US12162876B2 (en) Indazole kinase inhibitor and use thereof
AU2008200070A1 (en) Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases
CN120418248A (zh) 作为新型二酰基甘油酯o-酰基转移酶2抑制剂的三唑并吡啶衍生物的制备